Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells
Article first published online: 17 AUG 2012
© 2012 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1266, Hematopoietic Stem Cells VIII pages 179–188, August 2012
How to Cite
van Bekkum, D. W. and Mikkers, H. M.M. (2012), Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells. Annals of the New York Academy of Sciences, 1266: 179–188. doi: 10.1111/j.1749-6632.2012.06629.x
- Issue published online: 17 AUG 2012
- Article first published online: 17 AUG 2012
- induced pluripotent stem cells;
- hematopoietic stem cells;
Many life-threatening hematological diseases are now treated by bone marrow transplantations, i.e., infusion of hematopoietic stem cells (HSCs). HSC transplantations are a valid option for the treatment of a variety of metabolic disorders, and even for solid tumors and some refractory severe autoimmune diseases. Unfortunately, the frequency and outcome of HSC transplantations are limited by a shortage of suitable donors. Induced pluripotent stem cells (iPSCs)—somatic cells that have acquired pluripotent stem cell characteristics by the ectopic expression of pluripotency-inducing factors—have been proposed as an alternative source of HSCs. Possible applications include cells of autologous, of autologous and genetically modified, or of allogeneic origin. Here, we provide a perspective on the distinct opportunities of iPSCs and discuss the challenges that lie ahead.